Abstract: Process for preparing compounds of the formula (I) where R1, R2 and R3 are independently hydrogen, alkyl or cycloalkyl, characterized in that an aldehyde of the formula (II) is reacted with CH2(CN)2 in the presence of butanol.
Type:
Grant
Filed:
August 19, 2002
Date of Patent:
February 8, 2005
Assignee:
Bayer Aktiengesellschaft
Inventors:
Josef-Walter Stawitz, Stephan Michaelis, Christoph Thiebes
Abstract: The invention relates to a nickel mixed hydroxide with Ni as the main element and with a layer structure, comprising at least one element Ma from the group comprising Fe, Cr, Co, Ti, Zr and Cu which is present in two different oxidation states which differ by one electron in terms of the number of outer electrons; at least one element Mb from the group comprising B, Al, Ga, In and RE (rare earth metals) present in the trivalent oxidation state; optionally at least one element Mc from the group comprising Mg, Ca, Sr, Ba and Zn present in the divalent oxidation state; apart from the hydroxide, at least one additional anion from the group comprising halides, carbonate, sulfate, oxalate, acetate, borate and phosphate in a quantity sufficient to preserve the electroneutrality of the mixed hydroxide; and water of hydration in a quantity which stabilizes the relevant structure of the mixed hydroxide.
Type:
Grant
Filed:
December 14, 1999
Date of Patent:
February 1, 2005
Assignee:
H. C. Starck GmbH
Inventors:
Viktor Stoller, Armin Olbrich, Juliane Meese-Marktscheffel, Margret Wohlfahrt-Mehrens, Peter Axmann, Herbert Dittrich, Sandra Ströbele
Abstract: This invention relates to vulcanizable diene rubber compounds with a high capacity for the addition of sulfur to be varied while processing safety is maintained, for the production of improved rubber moldings, particularly tire components.
Abstract: A novel process allows a simple preparation of highly pure halogen-substituted dibenzyl alcohols by reduction of the corresponding halogen-substituted terephthalic acids and reaction with an alkylating agent, sulfuric acid, alkyl- or arylsulfonic acids. The highly pure halogen-substituted dibenzyl alcohols obtained are suitable in particular for preparing pharmaceutically or agrochemically active compounds.
Abstract: High purity ammonium dimolybdate or molybdenum oxide is produced by the pressure oxidation of low grade molybdenite concentrates or molybdenum intermediates. The process entails nearly complete oxidation of the sulfide minerals while optimizing the process chemistry and autoclave conditions to solubilize as little of the molybdenum values as possible. The autoclave discharge 12 is then subjected to a leaching step, either an alkaline leach 50, 400 or ammonium leach 250 process, before or after a liquid/solid separation step 20, 220, 410. The solution is then subjected to (a) filtration 60, 410, solvent extraction 70, 440, crystallization 90,450, and calcination 120, 480 or (b) filtration 260, 280, crystallization 290, and calcination 320 to produce a product suitable for chemical-grade molybdenum oxide 125, 325, 485.
Type:
Grant
Filed:
May 9, 2001
Date of Patent:
May 4, 2004
Assignee:
H. C. Starck, Inc.
Inventors:
Robert W. Balliett, Wolfgang Kummer, John E. Litz, Lawrence F. McHugh, Harry H. K. Nauta, Paul B. Queneau, Rong-Chien Wu
Abstract: A method of reducing the level of malodorous amines emitted by paper when exposed to an alkaline environment is provided, which comprises making the paper so that it does not contain ammonium groups that are bonded to any polymer contained in the paper by only one chemical bond. Laminates which emit reduced levels of amines and which are comprised of this paper are also provided. In a preferred embodiment, the paper is sized with a sizing emulsion comprised of alkenyl succinic anhydride and a cationic water-soluble polymer having ammonium groups that are attached to the polymer by at least two chemical bonds.
Abstract: Disclosed herein are a methods of treating therapeutically, or metaphylactically infected animals susceptible to, or infected animal suffering from parasitic neurologic or abortigenic diseases due to Sarcocystis, Neospora or Toxoplasma that are treatable with triazineone compounds by administering thereto a pharmaceutically effective amount of the compound, including a single high dose therapeutic treatment.